Co-incubation of Odronextab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Odronextamab was able to activate the NF-AT signaling pathway.

Odronextamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Odronextamab bound to huCD3e-jurkat cells, and the EC50 was 26.520 nM.

Odronextamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE), and test by flow cytometry. As shown in fig, Odronextamab bound to Raji cells, and the EC50 was 17.3 nM.

Odronextamab bound to CD20 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Odronextamab bound human CD20-VLP, and the EC50 was 0.1964 nM.

The purity of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 97.48%, determined by SEC-HPLC.

Anti-CD20 & CD3 Reference Antibody (Odronextamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.